<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: A subset of B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with blastoid features do not fit either as B lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:mpath ids='MPATH_336'>leukaemia</z:mpath> or blastoid mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Their classification is challenging, even with complete clinicopathological and genetic information </plain></SENT>
<SENT sid="2" pm="."><plain>At a haematopathology workshop, experts had suggested the term 'high-grade B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with blastoid features', and recommended further studies </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We describe the clinicopathological, immunophenotypic and cytogenetic findings of 24 high-grade B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, unclassifiable, with blastoid features </plain></SENT>
<SENT sid="4" pm="."><plain>Fifteen patients presented de novo and seven patients had a history of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty patients (83%) presented with nodal disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> expressed pan-B cell antigens and 17 (89%) of 19 tumours assessed had a germinal centre B cell immunophenotype </plain></SENT>
<SENT sid="7" pm="."><plain>Ten (63%) of 16 tumours assessed by fluorescence in-situ hybridization (FISH) had MYC rearrangement, 13 of 18 (72%) carried IGH-BCL2 and nine of 15 (60%) had both (double-hit <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>The median overall survival was 1.1 years </plain></SENT>
<SENT sid="9" pm="."><plain>Using 2008 World Health Organization criteria, 15 cases were classified as B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and nine as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, small <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> variant </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: High-grade B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, unclassifiable, with blastoid features are clinically aggressive with poor survival </plain></SENT>
<SENT sid="11" pm="."><plain>Most <z:hpo ids='HP_0002664'>neoplasms</z:hpo> have a germinal centre B <z:mp ids='MP_0005384'>cell phenotype</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>MYC rearrangements and IGH-BCL2 are common, and ~60% are double-hit <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>